Virginia Tech® home

Archived Seminar: Genetics of Invasive Glioblastoma Cells

Pioneers in Biomedical Research Seminar presented by the Fralin Biomedical Research Institute at VTC

Archived Seminar: The Genetics of Invasive Glioblastoma Cells

Date: Oct. 9, 2020
Time: 11:00 a.m. - 12:00 p.m.

Glioblastoma (GBM), the most common adult brain cancer, is among the most genetically heterogeneous, treatment resistant, and lethal of all human cancers. Despite the genetic heterogeneity, a unifying characteristic of GBM is aggressive cell invasion into the brain parenchyma, which prevents complete surgical removal, increases the risk profile of adjuvant therapies, and virtually assures tumor recurrence. Recurrent GBM tumors are generally less sensitive to therapy than the original tumor and in most cases are located in critical brain areas, preventing a second surgical resection. Most GBM molecular studies to date focus on primary, newly diagnosed tumors, and as a consequence our knowledge of recurrent GBM biology is limited. It is clear however, that primary and recurrent GBM are in some ways distinct diseases, with the latter tumors reflecting selective pressures exerted by the standard-of-care adjuvant treatment paradigm for primary GBM tumor treatment (radiation and temozolomide (TMZ). Paradoxically, even though the biology of recurrent GBM is not fully understood, most of the clinical trials testing new GBM therapeutic agents are in the setting of recurrence. Thus, additional studies focused on recurrent tumors are necessary in order to generate more molecular information on these tumors and to aid in the development of new therapies that target these aggressive cells. Accordingly, we have conducted comprehensive genomic and transcriptomic analyses of patient-matched primary and recurrent GBM patient tumor core specimens with the goal of identifying new therapeutic targets for recurrent disease. These initial studies have identified the important signaling node(s) in recurrent GBM and thus a potential vulnerability for targeted agents.

Additional Details 

This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Fralin Biomedical Research Institute Pioneers in Biomedical Research Program offers the expertise of a range of scientists who are exploring frontiers in biomedical research. These seminars are open to Virginia Tech and Carilion Clinic faculty, students, and staff.

 

You May Also Be Interested In...

  • Home Item
    Sudden Cardiac Arrest in the Young: The case of ARVC , home

    Oct. 18, 2024, 11:00 a.m. | Mario Delmar, M.D., Ph.D., Endowed Professor of Medicine, Patricia and Robert Martinsen Professor of Cardiology, Leon H Charney Division of Cardiology, New York University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research

  • Home Item
    Harnessing Interoception: Innovative Approaches for Psychiatric Assessment and Intervention , home

    Oct. 25, 2024, 11:00 a.m. | Sahib Khalsa, M.D., Ph.D., Associate Professor, Louis Jolyon West Innovation Chair, Director of Anxiety Disorders Research, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles| Co-Sponsored by the Center for Health Behaviors Research and the Addiction Recovery Research Center, Fralin Biomedical Research Institute

  • Home Item
    Clinical Applications of Cancer Genetics , home

    Nov. 21, 2024, 5:30 p.m. (Reception at 5 p.m.) | Luis Diaz, Jr., M.D., Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center; Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture

  • Home Item
    A Ribocentric View of Muscle Proteostasis in Health and Disease: Novel Mechanisms Potential Therapeutic Opportunities , home

    Nov. 22, 2024, 11:00 a.m. | Gustavo A. Nader, Ph.D., FAPS, Professor, College of Health and Human Development; Chair, Molecular, Cellular, and Integrative Physiology; Huck Institutes of the Life Sciences; The Pennsylvania State University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research

  • Home Item
    Human Laboratory Evaluation of Cannabis Products , home

    Dec. 13, 2024, 11:00 a.m. | Ryan Vandrey, Ph.D., Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and the Addiction Recovery Research Center

Nhan Tran, Ph.D. to present at Fralin Biomedical Research Institute

Nhan Tran, Ph.D.

Professor in the Department of Cancer Biology at Mayo Clinic